Legal Battles, Breakthrough Trials & a $3M Honor in Obesity Drug Innovation! ⚖️💥
In this week’s Obesity Updates, we break down the most impactful developments shaping the obesity drug landscape—from first-in-human trials to legal crackdowns and Medicare shocks.
Key updates include:
💉 Antag Therapeutics begins first-in-human trial for GIPR-targeting obesity drug AT-7687.
🇰🇷 Korea United Pharm enters semaglutide biosimilar race with clinical trials and 2029 facility plans.
📊 Prime Therapeutics presents real-world GLP-1 data at AMCP, earning “Article of the Year.”
🏆 GLP-1 developers win $3M Breakthrough Prize for Ozempic and Wegovy innovation.
⚖️ Eli Lilly sues compounders over unauthorized tirzepatide sales and cuts official pricing.
🛑 Medicare excludes obesity drugs from 2026 coverage.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityTreatment #GLP1 #WeightLossDrugs #HealthcareInnovation #ObesityResearch #Tirzepatide #Ozempic #Wegovy #MedicareNews #PharmaLawsuits #ClinicalTrials #LucidQuest #BiotechNews